TMDX vs. NVO

In the year-to-date period, TMDX achieves a 49.96% return, which is significantly higher than NVO's -26.67% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for TransMedics Group, Inc. (TMDX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TMDX Sharpe Ratio is 0.05, which is higher than the NVO Sharpe Ratio of -1.22. The chart below compares the historical Sharpe Ratios of TMDX and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

TMDX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 2.60%.

The maximum TMDX drawdown since its inception was -73.69%, roughly equal to the maximum NVO drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for TMDX and NVO. For additional features, visit the drawdowns tool.

TransMedics Group, Inc. (TMDX) and Novo Nordisk A/S (NVO) have volatilities of 17.52% and 16.79%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between TransMedics Group, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.